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Children with biallelic mutations in FANCD1/BRCA2 are at uniquely high risks of leukemia and solid tumors.
Preemptive bone marrow transplantation (PE-BMT) has been proposed to avoid the development of leuke-
mia, but empirical study of PE-BMT is unlikely because of the rarity of these children and the unknown
beneﬁt of PE-BMT. We used survival analysis to estimate the risks of leukemia and the expected survival if
leukemia could be eliminated by curative PE-BMT. We used the results in a decision analysis model to explore
the plausibility of PE-BMT for children with variable ages at diagnosis and risks of transplantation-related
mortality. For example, PE-BMT at 1 year of age with a 10% risk of transplantation-related mortality
increased the mean survival by 1.7 years. The greatest beneﬁt was for patients diagnosed between 1 and
3 years of age, after which the beneﬁt of PE-BMT decreased with age at diagnosis, and the risk of death from
solid tumors constituted a relatively greater burden of mortality. Our methods may be used to model survival
for other hematologic disorders with limited empirical data and a pressing need for clinical guidance.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Fanconi anemia (FA) is a primarily autosomal recessive
inherited bone marrow failure and cancer predisposition
syndrome, caused by germline mutations in more than 16
genes involved in the FA/BRCA DNA damage response
pathway [1]. Patients with FA have an approximately 800-
fold increased risk of developing leukemia and an overall
risk of more than 50-fold for any malignancy or solid tumor;
the cumulative incidence of severe bone marrow failure is
more than 50% by age 45 years [2]. Characteristic birth de-
fects frequently associated with FA include short stature, café
au lait spots, microcephaly, thumb and radial anomalies, and
renal structural defects [1]. Biallelic mutations in FANCD1/
BRCA2 have been reported in rare patients with FA with very
early-onset leukemia and solid tumors. An analysis of 27
published cases with these mutations found that the cu-
mulative incidence of any malignancy was 97% by 6 years of
age and the actuarial risks of leukemia and solid tumor were
79% by 10 years of age and 83% by 7 years of age [3].
Bone marrow transplantation (BMT) is currently the
only treatment that has the potential to restore normaledgments on page 1800.
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who have bone marrow failure, myelodysplastic syndrome
(MDS), or leukemia [4]. The best results were found in recent
European experience to involve a matched family donor,
patients younger than 10 years of age, transplantation
without irradiation, and bone marrow failure without MDS
or leukemia, similar to earlier results from the Center for
International Blood andMarrow Transplant Research [5,6]. In
patients with FA, overall 5-year survival of 80% to 90%may be
expected for matched sibling donor transplantation versus
60% to 75% for transplants from unrelated donors [5]. Sur-
vival is lower in patients with hematologic malignancies, in
part because of the more frequent use of mismatched or
unrelated donors and more intensive marrow suppression.
Patients with FA due to biallelic mutations in FANCD1/
BRCA2 have an inordinately high and early risk of leukemia,
leading to the suggestion that earlier transplantation be
considered before the development of severe cytopenias
[4]. There are no published data on the results of such
transplantations, however. Through 2013, 10 patients with
FANCD1/BRCA2 who underwent transplantation after they
had developed leukemia (with 1 exception who had neu-
tropenia, see Table 1) were reported, with only 2 survivors
[7-12]. Seven died less than 1 year after transplantation.
These patients were not ideal candidates for transplantation,
as 8 had acute myeloid leukemia and 1 acute lymphoblasticMarrow Transplantation.
Table 1
Hematopoietic Stem Cell Transplantation in Patients with FANCD1/BRCA2 Mutations Reported in the Literature, 2000 to 2013
ID Age at Hematologic
Abnormality, yr
Reason
for BMT
Age at
BMT, yr
Interval Survival
after BMT, yr
Donor Stem Cell
Source
Outcome Age at Last
Report, yr
Reference
AP37P 2.0 AML 2.2 1.67 HLA identical sibling BM Dead 3.87 [7]
632/1 3.0 AML 3.7 0.33 6/6 URD BM Dead 4.0 [8,9]
632/2 1.75 AML 1.9 0.80 6/6 MSD BM Dead 2.7
800/1 0.9 AML 1.8 0.34 6/6 URD TCD BM Dead 2.1
800/2 0.9 Neutropenia 0.8 0.17 6/6 URD TCD BM Dead 0.97
900/1 5.2 ALL 4.9 2.50 5/6 Mother TCD BM Alive 7.4
984/2 4.9 ALL-AML* 6.7 0.58 6/6 URD UCB Alive 7.3
2751 5.5 AML 5.5 0.50 4/6 and 7/10 related PB Dead 6.0 [10]
PT 2 1.7 AML 1.7 0.40 MUD 8/8 NA Dead 2.1 [11]
Case 2.0 AML 2.0 0.83 HLA identical sibling BM Dead 2.8 [12]
ID indicates identiﬁer; AML, acute myeloid leukemia; BM, bone marrow; URD, unrelated donor; MSD, matched sibling donor; TCD, T cell depleted; ALL, acute
lymphoblastic leukemia; UCB, umbilical cord blood; PB, peripheral blood; PT 2, patient 2; MUD, matched unrelated donor; NA, not available.
* Patient had T cell ALL at 4.9 yrs of age, went into remission with chemotherapy, and relapsed with AML at 6.3 yrs of age. While being worked up for BMT, a
Wilms tumor was found; after nephrectomy, the patient proceeded to transplantation at age 6.7 yrs.
Figure 1. Markov decision model for children with FANCD1/BRCA2. Hypo-
thetical cases transition through the model in 3-month intervals. (A) Begin-
ning in the alive state, patients receiving standard care are at risk of dying
from any cause similar to what is expected historically (leukemia or solid
tumors). (B) Patients receiving PE-BMT are at risk of dying from causes related
to transplantation or from causes other than leukemia, such as solid tumors.
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unrelated donors, and 2 had partially matched related do-
nors. Cord blood was used in 1 case, peripheral blood in 1,
and bone marrow in the others.
BMT before the development of symptomatic hemato-
logic problems might increase overall survival in patients
with FA, particularly in those with FANCD1/BRCA2. Healthy
transplant recipients (even with FA) would presumably have
better tolerance of the complications associated with a BMT,
and a successful transplantation is anticipated to eliminate
the future risk of MDS or leukemia. We have chosen to call
this type of transplantation “preemptive” (PE-BMT) [15], as it
is preventive, rather than early, which implies that the
outcome being avoided is inevitable, and the only issue is the
timing. In reality, only about one half of the patients with
FANCD1/BRCA2 are predicted to develop leukemia in their
lifetime because of the competing risks of solid tumors and
death. However, BMT carries nontrivial risks of mortality and
morbidity, and exposing an otherwise healthy child to a risky
procedure of unknown beneﬁt violates “primum non nocere
(ﬁrst do no harm)” [16]. A clinical trial of PE-BMT in those
with FANCD1/BRCA2 is not feasible because of the rarity of
such patients and the uncertainty regarding the risks and
potential rewards of transplantation in this population.
To address this question, we used statistical methods and
decision analysis to explore the utility of PE-BMT in this
context. Decision analysis provides a mathematical structure
for weighing the risks and beneﬁts of competing strategies.
We estimated the overall survival curve if leukemia could be
eliminated from the FANCD1/BRCA2 population (actuarial
risks) and used the results in a decision analysis to examine
the possible beneﬁts of PE-BMT compared with current
standard care. We relied on the limited number of published
cases with FANCD1/BRCA2 for data on overall survival and
development of malignant complications (acute myeloid
leukemia, brain tumors, Wilms tumors, and other solid tu-
mors) before BMT [3,10-12,17-19].
METHODS
Decision Model
We developed a Markov decision model from the parental perspective
to determine how PE-BMT at 1 year of age would affect the mean survival of
children with FANCD1/BRCA2 compared with a strategy of standard care
according to the recent literature reports. Markov, or state-transition,
models allow for the recursive simulation of events and risks that change
over time and have been used by others to simulate outcomes of BMT
strategies in the presence of uncertainty [20-22]. In our Markov model, a
cohort of hypothetical cases transition between 2 mutually exclusive
statesdalive and deaddover multiple cycles (Figure 1). All hypotheticalcases begin in the alive state and transition over time to the dead state,
out of which they cannot transition. Cases receiving standard care have a
probability of transitioning to the dead state that is equal to the age-
dependent conditional probability of dying among cases reported in the
literature. Children with FANCD1/BRCA2 receiving PE-BMT are at risk of
dying from malignancies other than leukemia or from transplantation-
related mortality (TRM). TRM is the excess mortality attributable to BMT,
including risks of infection, graft-versus-host disease (GVHD), and regimen-
related toxicity, which is distinct from other causes of death in this popu-
lation, such as solid tumors. We biased our model in favor of PE-BMT and
posited that PE-BMT would not affect the incidence of solid tumors or other
causes of death and that the risk of leukemia would be eliminated. BMT in
other FA complementation groups was associated with an increased inci-
dence of head and neck squamous cell carcinoma comparedwith FA patients
who did not have a BMT [23]. However, cancer risks associated with more
recent conditioning regimens may be lower, and the solid tumors (midline
brain, and Wilms tumors) observed in FANCD1/BRCA2 are different from
those in other FA groups (head and neck and gynecologic squamous cell
carcinomas); the risks may not be increased by BMT or GVHD.
We chose a cycle length of 3 months, evaluated the decision over 160
cycles, or 40 years duration after transplantation, and we assumed that all
events occur half-way through each cycle (“half-cycle correction”) [24]. We
did not adjust the expected survival to reﬂect decrements in quality of life
because we could not ﬁnd health-state utilities from the parental perspec-
tive applicable to our very young population. Hence, we developed a model
to provide objective estimates of survival to be used by parents in the
context of a family’s values and circumstances. We also did not discount the
value of future life-years. We modeled the decision conditioned on survival
to ages ranging from 3 months to 10 years to determine at what ages
PE-BMT might remain feasible; this analysis informs the decision for pa-
tients diagnosed with FA at various ages. All annual probabilities and rates
were transformed to the appropriate 3-month equivalents (see Supplement
for details). The decision model was implemented in TreeAge Pro 2014
(TreeAge Software, Inc, Williamstown, MA).Data Sources
We included the 36 cases of patients with FANCD1/BRCA2 published
between the years 2000 through 2013 in our analysis [3,10-12,17-19]. We
ﬁt several parametric survival curves, including exponential, Weibull,
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any cause of death, and we used Akaike information criterion and visual
inspection to assess goodness-of-ﬁt. We estimated the (hypothetical) actu-
arial survival of children with FANCD1/BRCA2 if leukemia could be elimi-
nated from this population by censoring cases at the development of
leukemia and counting death as an event. We calculated the cumulative
incidence function in the presence of competing risks [25] and the com-
plement of the Kaplan-Meier product-limit estimators [26] to determine the
crude and actuarial risks, respectively, of leukemia and other causes of
death. Whereas the crude risk reﬂects the proportion of patients who
experience an event, the actuarial risk represents the hypothetical propor-
tion of patients who would experience an event if the risks of competing
events could be removed. All survival analyses were conducted using Stata/
SE 13.1 (StataCorp LP, College Station, TX).
The presumptive advantage of PE-BMT is that providing transplantation
to healthy children with FA without leukemia would yield better outcomes
than providing transplantation to such children presenting with leukemia,
and that by eliminating the risk of leukemia from this population, the
children would have greater overall survival. However, because of the
particularly early onset of leukemia in these children, an effective policy of
preemption would require transplantation during infancy, an age group for
which there are no data on TRM for FA. Rather than compare infants with
FANCD1/BRCA2 to adolescents with FA in other complementation groups, we
consulted recent publications on BMT in infants with severe combined
immunodeﬁciency or Hurler syndrome who received a BMT within the ﬁrst
year of life (and were without infection at the time of BMT) to estimate a
plausible risk of TRM (10%) in otherwise healthy infants (ie, those without a
malignancy) [27,28]. For our base case of a 1-year-old patient with FANCD1/
BRCA2, we assumed that the cumulative probability of TRM was 10%
and that this risk would be spread evenly over the ﬁrst year after
transplantation.
Sensitivity Analysis
We varied the decision over a range of ages at BMT and of risks of TRM
(Table 2). Long-term survival after BMT in infants and young children with
nonmalignant disorders, such as severe combined immunodeﬁciency or
Hurler syndrome, was reported to range from 50% to 95%, with most of the
mortality occurring within the ﬁrst year after BMT [27,28]. We thus explored
how the decision would change over a wide range of TRM, between 0% and
60% over 1 year after transplantation. We performed 1-way and 2-way
sensitivity analyses and present threshold values of TRM at which a given
strategy has superior mean survival.
RESULTS
Survival Analysis
We determined that log-logistic functions provided the
best ﬁt for estimating both overall survival and the hypo-
thetical survival if leukemia could be eliminated from the
published FANCD1/BRCA2 population (see Supplement for
parameterizations). The median overall survival estimated
by the parametric models was 3.5 years of age and the 10-
year overall survival was 8% (Figure 2A). The crude risks of
leukemia and death from other causes after treating these as
competing risks were 49% (95% conﬁdence interval [CI], 32%
to 65%) and 48% (95% CI, 30% to 63%) by 10 years of age,
respectively (Figure 2B). The actuarial risk of leukemia (if the
risk of death from other causes could be removed) was 79%
(95% CI, 53% to 95%) by 10 years of age. If the risk of leukemia
could be eliminated in this population, the median survival
would be 5 years of age and the 10-year overall survivalTable 2
Markov Model Parameters and Range Tested in Sensitivity Analysis
Model Parameter Base Case
Value(s)
Range Used
in Sensitivity
Analysis
Source
Overall survival Age dependent * Figure 2A
TRM over 1 yr 10% 0%-60% Pai et al. [27]
Survival after PE-BMT Age-dependent * Figure 2C
Age at decision 1 yr .25-10 yr N/A
N/A indicates not available.
* Probabilities were not varied in sensitivity analysis.would be 19% (Figure 2C) because of the high risk of brain
and Wilms tumors in this population. The per-year hazard
(rate) of death from any cause (mainly leukemia or solid
tumors) was largest at 4 years of age (Figure 2D, dotted line).
The hazard of death from causes other than leukemia would
peak around 5 years of age if the risk of leukemia could be
removed (solid line).
BASE CASE RESULTS AND SENSITIVITY ANALYSES
For 1-year-old patients receiving standard care, the mean
survival was an additional 4.1 years, the median survival
was an additional 2.8 years, and overall survival after 5
years and 10 years was 24% and 7%, respectively (Figure 3A,
dotted line). Under a base case strategy of PE-BMT at age
1 year and a 10% risk of TRM over 1 year (solid line), the
mean survival was an additional 5.8 years, the median
survival was an additional 3.8 years, and overall survival 5
and 10 years after transplantation was 39% and 15%,
respectively. Thus, PE-BMT at 1 year of age increased the
mean survival by 1.7 years and the median survival by
1.0 years; hence, PE-BMT was the dominant strategy under
base case assumptions. Similar analyses are shown in
Figure 3B and C, suggesting that PE-BMT provides the most
survival beneﬁt when performed when the child is younger
than 3 years of age.
As noted above, for children diagnosed at 1 year of age,
the expected survival with no intervention is an additional
4.1 years (Figure 4A). PE-BMT would increase the mean
survival by 2.3 years if there were no TRM (Figure 4B) or
1.7 years with a 10% risk of TRM, and PE-BMT would remain
the superior strategy so long as the risk of TRM over 1 year
was 38% or lower. If instead PE-BMT carried a 60% risk of
TRM, the expected survival would decrease by 1.3 years.
Consider next a child presenting at 6 months of age. The
mean survival expected in the absence of PE-BMT is an
additional 4.5 years (Figure 4A). PE-BMT with a 10% risk of
TRM would increase the expected survival by 1.7 years
(Figure 4B). If the decisionwere made for a child of 3 years of
age, the expected survival would increase by a similar
amount, 1.6 years. More generally, PE-BMT remained a viable
option at low risks of TRM but ceased being the superior
strategy for children presenting at ages older than 5 years
with risks of TRM greater than 30%. However, the small
numbers of published cases of older children and adoles-
cents with FANCD1/BRCA2 limit our conﬁdence in projections
made for children presenting for PE-BMT at ages older than
3 years.
DISCUSSION
PE-BMT may increase the mean survival of children with
FANCD1/BRCA2 if the procedure is safe enough and the
timing is early enough. In our modeling scenarios, “safe
enough” in this high-risk setting corresponds to 1-year TRM
below 30% and “early enough” is providing transplantation
for children younger than 5 years of age. The potential
beneﬁt of PE-BMT was very sensitive to the risk of TRM but
less sensitive to the age at PE-BMT. Our results depend on the
validity of our parametric models for the competing risks of
death from leukemia and other causes, which include solid
tumors, especially brain and Wilms tumors. However, our
risk estimates reﬂect the totality of cases reported through
2013, and our modeled survival curves appear to adequately
recapitulate the observed experience.
Although the permissible risk of TRM for PE-BMT is
higher thanwhat has been reported in BMT among children
Figure 2. Survival in patients with FANCD1/BRCA2. (A) Overall survival. Both nonparametric Kaplan-Meier (solid line) and log-logistic parametric (dotted line)
estimators indicate poor survival; less than 10% are expected to survive into their teens. Shaded area indicates 95% conﬁdence intervals. The last survivor was lost to
follow-up at age 30. (B) Crude and actuarial risks of leukemia. The actuarial risk of developing leukemia (dotted line) is 79% by age 10. Treating leukemia and death
from other causes as competing risks, the crude risks of leukemia (solid line) and death from other causes (dashed line) are 49% and 48% by age 10, respectively. The
vertical lines indicate the 95% conﬁdence intervals at those ﬁxed ages. (C) Survival if the risk of leukemia could be eliminated. We censored at the development of
leukemia. Both nonparametric Kaplan-Meier (solid line) and parametric log-logistic (dotted line) functions estimated that in the absence of leukemia, 20% would
survive until age 10. (D) Annual hazard rates. We plotted the per-year hazard rates for overall survival (dotted line) and survival if leukemia could be eliminated by
PE-BMT (solid line). The hazard rate for overall survival peaks between 4 and 5 years of age while the hazard rate for survival if leukemia could be eliminated peaks at
5 years of age.
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infants who undergo transplantation for other conditions
[27,28], the expected survival after PE-BMT is still notably
short because of the greater competing risks. Even if there
were no risk of TRM from PE-BMT, the median survival of
this population would be 5 years of age because of
the mortality imposed by the solid tumors (Figure 2C).
Improved treatment regimens for the solid tumors associ-
ated with FANCD1/BRCA2 are likely to play as big a role in
increasing life expectancy as will improvements in survival
after BMT.Figure 3. Simulated survival curves for cohorts of children presenting for PE-BMT.
children receiving PE-BMT at age 1 year (solid lines) compared with what could b
presentation at 3 years of age. (C) PE-BMT after presentation at 5 years of age. EstimWe did not explicitly model the inﬂuence of donor and
stem cell source. Among FA patients with other comple-
mentation groups who underwent transplantation for any
reason between the years 2000 and 2009, nonrelapse mor-
tality after 1 year was 14% for those with matched sibling
donors versus 24% for those with matched unrelated donors
(nonrelapse mortality is a proxy for TRM) [5]. PE-BMTwould,
thus, seem a viable option for many with matched sibling
donors but for relatively fewwithmatched unrelated donors.
Importantly, an individualized risk of TRM for any given
patient-donor combination depends on a number of risk(A) PE-BMT after presentation at 1 year of age. Simulated survival curve for
e expected if no preemptive action is taken (dotted lines). (B) PE-BMT after
ates rely heavily on extrapolation.
Figure 4. Expected survival of children presenting at ages up to 10 years. (A) Expected survival of children with no PE-BMT. The expected (mean) survival of children
(y-axis) after presenting at age in years (x-axis). If no preemptive action is taken, a child presenting at 1 year of age is expected to survive an additional 4 years. (B) The
net gain/loss in expected survival from PE-BMT. The additional expected life-years gained or lost (y-axis) by receiving PE-BMT at an age at presentation ranging from
birth to 10 years (x-axis) and risk of TRM ranging from 0% to 60% over 1 year (dotted lines). PE-BMT at 1 year of age and a 10% risk of TRMwould increase the expected
survival by 1.7 years. Estimates for ages greater than 3 years rely heavily on extrapolation.
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donor-recipient gender or cytomegalovirus status mismatch,
and conditioning regimendfactors that are not formally
included in our model. These factors should be qualitatively
assessed as increasing or decreasing the risk for the indi-
vidual patient at hand versus the population average risk.
Whether parents would elect for their child to undergo
PE-BMT is unknown if the survival beneﬁt offered by PE-BMT
is only marginal; if there were no risk of TRM, an optimally
timed preemptive transplantation would increase the mean
survival by less than 2.5 years. There is also a potential ethical
concern about performing a risky procedure on an appar-
ently healthy child. For example, in a study of parental de-
cision making for children with sickle cell disease, 15% of
parents stated they would refuse a curative bone marrow
transplantation even if therewere no excess risk of mortality,
and only 36% of parents were willing to accept a 15% or
greater risk of short-term mortality [30]. Although children
with sickle cell disease do not face the same types of risks as
children with FANCD1/BRCA2, the aversion to BMT for sickle
cell disease in the absence of symptoms is illustrative of
parental aversion to any procedural risk.
The quality of life for patients with FANCD1/BRCA2 and for
their families should also factor into shared decision making.
This is complicated, as the parents are proxies for their young
children, and it is difﬁcult to evaluate using traditional
quality of life instruments in this context. Certainly, BMT in
pediatric populations is associated with decreased quality of
life that has both physical and psychosocial bases. Develop-
ment of GVHD and infection are associated with a worse
quality of life [31]. In addition, children who receive BMT are
kept in protective isolation, both inside and outside the
hospital in the months after BMT, which may affect their
development at a critical time. Neurocognitive delays were
found to be most signiﬁcant in young patients (ages 0 to
3 years), particularly in those who had received total body
irradiation [32]. It is difﬁcult to estimate how hospitalization
per se impacts the development of children. Even for those
who do not undergo BMT, management of solid tumors in
this population may also interfere with development and
lead to signiﬁcant other late effects [33].
Despite obvious limitations of decision analysis method-
ology, our results provide an objective quantiﬁcation of risks
versus beneﬁts that can help parents and physicians decidewhether or not to pursue PE-BMT for children with FANCD1/
BRCA2. Furthermore, the methods discussed here can be
utilized in the context of other disorders for which hema-
tologic malignancy is a major concern.
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